




RealRate

PHARMACEUTICAL 2018

Syndax Pharmaceuticals Inc
Rank 163 of 349

Syndax



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 237% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is -156%, being 122% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	133,442
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,798
Liabilities, Non-Current	17,069
Other Assets	3,477
Other Compr. Net Income	-199
Other Expenses	0
Other Liabilities	0
Other Net Income	3,260
Property and Equipment	267
Research and Development	48,201
Revenues	0
Selling, General and Administrative Expense	15,861

Output Variable	Value in 1000 USD
Assets	137,186
Liabilities	32,867
Expenses	64,062
Stockholders Equity	104,319
Net Income	-60,802
Comprehensive Net Income	-60,902
Economic Capital Ratio	-156%